Last reviewed · How we verify
NCT06874751: SCORE
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
trial testing No treatment given in Overweight in 45,456 participants. Completed in 28 March 2025.
28 March 2025
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 45,456 |
| Start date | 6 December 2024 |
| Primary completion | 28 March 2025 |
| Estimated completion | 28 March 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- No treatment given — full drug profile →
- No treatment given — full drug profile →
Conditions studied
- Overweight — all drugs for Overweight →
- Obesity — all drugs for Obesity →
- Atherosclerotic Cardiovascular Disease (ASCVD) — all drugs for Atherosclerotic Cardiovascular Disease (ASCVD) →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
45 and older, any sex, with Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outcomes.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
Smolderen KG, Mena-Hurtado C, Zhao Z, Michalak W, et al · · 2025 · cited 3× · PMID 40926360 · DOI 10.1111/dom.70080 -
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases.
Apperloo EM, Heerspink HJL, van Raalte DH, Muskiet MHA. · · 2026 · cited 1× · PMID 40560166 · DOI 10.1093/ndt/gfaf110 -
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.
Nanna MG, Mena-Hurtado C, Divino V, Zhao Z, et al · · 2026 · PMID 41889157 · DOI 10.1111/dom.70686
Verify or expand the search:
- PubMed search for NCT06874751
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No treatment given
Trials testing the same drug.
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07358052 — Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE） · completed
- NCT07201831 — A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation · completed
- NCT07154238 — Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sec · enrolling by invitation
- NCT07160829 — Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Hear · completed
Other recruiting trials for Overweight
Currently open trials in the same condition.
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
- NCT07465965 — A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults · Phase 1 · recruiting
- NCT07407348 — A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the · Phase 1 · recruiting
- NCT07400653 — A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06874751 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06874751.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing